<DOC>
	<DOC>NCT00004479</DOC>
	<brief_summary>OBJECTIVES: Determine the efficacy of midodrine, a selective alpha 1 adrenergic agonist, in preventing neurally mediated syncope.</brief_summary>
	<brief_title>Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double-blind, crossover, placebo-controlled study. On day one, patients receive either midodrine or placebo. On day three, patients receive the opposite drug.</detailed_description>
	<mesh_term>Syncope</mesh_term>
	<mesh_term>Adrenergic Agonists</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Diagnosis of neurally mediated syncope (vasovagal fainting) Sudden fall in blood pressure AND Slowing of the heart AND Temporary loss of consciousness AND Hemodynamic response to head up tilt Prior/Concurrent Therapy No other concurrent adrenergic agonist or antiagonist Patient Characteristics Fertile patients must use effective birth control</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>neurologic and psychiatric disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>syncope</keyword>
</DOC>